razoxane has been researched along with Bone Cancer in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Durand, JB; Herzog, CE; Huh, WW; Jaffe, N; Munsell, MF | 1 |
| Bahrami, A; Davidoff, AM; Fernandez-Pineda, I; Green, JF; McGregor, LM; Sandoval, JA | 1 |
| Chintagumpala, M; Davino, N; Helman, L; Hicks, J; Johnson, M; Lau, CC; Man, TK; Meyer, W; Murray, J; Perlaky, L; Shen, J; Triche, T; Visvanathan, J; Wong, KK | 1 |
| Campos Filho, O; Carvalho, AC; de Matos Neto, RP; Gomes, Lde F; Moisés, VA; Oporto, VM; Paiva, MG; Petrilli, AS; Silva, CM | 1 |
| Clauw, DJ; Natale, RB; Ruddon, RW; Wheeler, RH | 1 |
| Ash, A; Borden, EC; Enterline, HT; Falkson, G; Laucius, JF; Lerner, H; Paul, AR; Rosenbaum, C | 1 |
| Bates, T; Hellmann, K; Newton, KA; Ryall, RD | 1 |
1 review(s) available for razoxane and Bone Cancer
| Article | Year |
|---|---|
Isolated subcutaneous metastasis of osteosarcoma 5 years after initial diagnosis.
Topics: Abdominal Wall; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcinosis; Cisplatin; Combined Modality Therapy; Doxorubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Methotrexate; Neoadjuvant Therapy; Organ Sparing Treatments; Osteosarcoma; Radiography; Razoxane; Receptor, IGF Type 1; Skin Neoplasms; Subcutaneous Tissue; Tibia; Time Factors; Young Adult | 2011 |
1 trial(s) available for razoxane and Bone Cancer
| Article | Year |
|---|---|
Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Doxorubicin; Echocardiography; Female; Humans; Male; Osteosarcoma; Prospective Studies; Razoxane; Ventricular Function, Left | 2006 |
5 other study(ies) available for razoxane and Bone Cancer
| Article | Year |
|---|---|
Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Cohort Studies; Doxorubicin; Electrocardiography; Female; Humans; Infusions, Intravenous; Male; Osteosarcoma; Razoxane; Retrospective Studies; Risk Factors; Ventricular Dysfunction; Young Adult | 2010 |
Expression profiles of osteosarcoma that can predict response to chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Child; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Nuclear Proteins; Osteosarcoma; Predictive Value of Tests; Prognosis; Razoxane; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Twist-Related Protein 1 | 2005 |
The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo.
Topics: Antineoplastic Agents; Bone Marrow Cells; Bone Neoplasms; Burkitt Lymphoma; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Drug Evaluation; Humans; Kinetics; Lung Neoplasms; Mitosis; Piperazines; Razoxane; Stereoisomerism; Thymidine | 1983 |
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Drug Evaluation; Female; Humans; Male; Maytansine; Mesothelioma; Middle Aged; Mitolactol; Osteosarcoma; Oxazines; Piperazines; Prognosis; Random Allocation; Razoxane; Sarcoma; Soft Tissue Neoplasms | 1982 |
Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma.
Topics: Adult; Aged; Bone Neoplasms; Chondrosarcoma; Female; Humans; Male; Middle Aged; Piperazines; Radiotherapy, High-Energy; Razoxane; Remission, Spontaneous; Soft Tissue Neoplasms; Time Factors | 1979 |